<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673474</url>
  </required_header>
  <id_info>
    <org_study_id>HM022BC1S02</org_study_id>
    <nct_id>NCT04673474</nct_id>
  </id_info>
  <brief_title>A Food-Effect Study of Hemay022 in Healthy Participants</brief_title>
  <official_title>A PhaseⅠFood-Effect Study of Hemay022 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Hemay Oncology Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Hemay Oncology Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effect of food in healthy&#xD;
      participants on the bioavailability of Hemay022 following single dose administration with and&#xD;
      without a meal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1: 0-48 hours; Day 8: 0-48 hours</time_frame>
    <description>Maximum Observed Plasma Concentration for Hemay022</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1: 0-48 hours; Day 8: 0-48 hours</time_frame>
    <description>Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Hemay022</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 1: 0-48 hours; Day 8: 0-48 hours</time_frame>
    <description>AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Hemay022</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 1: 0-48 hours; Day 8: 0-48 hours</time_frame>
    <description>Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for Hemay022</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Food-drug Interaction</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemay022 Period 1, Fasted control → Period 2, Fed control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemay022 Period 1, Fed control → Period 2, Fasted control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemay022</intervention_name>
    <description>Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemay022</intervention_name>
    <description>Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-40 years old, the ratio of male to female is 1:1, the age difference of the&#xD;
             same batch of subjects is less than 10 years;&#xD;
&#xD;
          2. Weight: male should not be less than 50kg, female should be no less than 45kg, body&#xD;
             mass index (BMI) [=weight (kg)/height 2 (m2)] between 19-24 (including boundary&#xD;
             values);&#xD;
&#xD;
          3. 90mmHg≤systolic blood pressure≤140mmHg, 60mmHg≤diastolic blood pressure≤90 mmHg, 55&#xD;
             beats/min≤pulse≤100 beats/min, 12 breaths/min≤respiration≤24 breaths/min, normal body&#xD;
             temperature;&#xD;
&#xD;
          4. Before the trial, the subjects have understood the nature, significance, possible&#xD;
             benefits and possible inconveniences and potential dangers of the trial in detail, and&#xD;
             volunteered to participate in the clinical trial, can communicate well with the&#xD;
             investigator, comply with the requirements of the entire study, and Signed a written&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participated in other drug clinical trials within 3 months;&#xD;
&#xD;
          2. (Inquiry)Diseases with abnormal clinical manifestations that need to be excluded,&#xD;
             including but not limited to diseases of the nervous system, cardiovascular system,&#xD;
             blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract,&#xD;
             respiratory system, metabolism and bones;&#xD;
&#xD;
          3. (Inquiry)Those who have a history of severe vomiting, diarrhea or any other diseases&#xD;
             or physiological conditions that can interfere with the study results within 7 days&#xD;
             before the trial;&#xD;
&#xD;
          4. (Inquiry)People with a history of specific allergies (asthma, urticaria, eczema,&#xD;
             etc.), or allergies (such as those who are allergic to two or more drugs, food or&#xD;
             pollen), or those who are known to be allergic to tiniba drugs;&#xD;
&#xD;
          5. (Inquiry) Those who lost blood or donated more than 400ml of blood within 3 months&#xD;
             before this clinical trial, or plan to donate blood during the trial;&#xD;
&#xD;
          6. Inquiry) Pregnant or lactating female, or subjects (including male subjects) have a&#xD;
             childbirth plan or sperm donation plan within 3 months after the last dose, unwilling&#xD;
             or unwilling Those who take effective contraceptive measures;&#xD;
&#xD;
          7. General physical examination and laboratory examination (blood routine, stool routine,&#xD;
             blood biochemistry, coagulation function, urine routine, blood human chorionic&#xD;
             gonadotropin/urinary pregnancy (female), etc.) within 7 days before the test, 6 months&#xD;
             before the test The result of internal chest radiograph is judged by clinicians as&#xD;
             abnormal and clinically significant;&#xD;
&#xD;
          8. Subjects whose left ventricular ejection fraction (LVEF) measured by MUGA scan or&#xD;
             echocardiography is less than 50%;&#xD;
&#xD;
          9. Patients with clinically significant ECG abnormalities in the 14 days before the test,&#xD;
             including: QTc (corrected by bazett or fridericia) interval prolonged (≥450ms) on the&#xD;
             screening ECG, QRS&gt;120ms;&#xD;
&#xD;
         10. One or more test results of hepatitis B surface antigen, hepatitis C virus antibody,&#xD;
             anti-human immunodeficiency virus antibody or Treponema pallidum antibody are&#xD;
             positive;&#xD;
&#xD;
         11. (Inquiry) Those who have suffered from a clinically significant disease or have&#xD;
             undergone major surgery within 3 months before the trial;&#xD;
&#xD;
         12. (Inquiry) Drinking more than 14 units per week (1 unit = 17.7 mL ethanol, ie 1 unit =&#xD;
             357 mL of beer with 5% alcohol content or 43 mL of liquor with 40% alcohol content or&#xD;
             147 mL of wine with 12% alcohol content), or those who cannot abstain from alcohol&#xD;
             during the test;&#xD;
&#xD;
         13. (Inquiry) Those who smoked more than 5 cigarettes a day on average in the 3 months&#xD;
             before the test, or who could not stop using any tobacco products during the test;&#xD;
&#xD;
         14. (Inquiry) People who drank excessive amounts of tea, coffee and/or caffeine-rich&#xD;
             beverages (more than 8 cups, 1 cup = 250 mL) during the 3 months before screening;&#xD;
&#xD;
         15. (Inquiry) Have taken grapefruit (including grapefruit), pomegranate, lime, carambola,&#xD;
             dragon fruit, mango and other fruits or food or beverages prepared therefrom within 7&#xD;
             days before screening;&#xD;
&#xD;
         16. (Inquiry) People who have eaten chocolate, caffeine-rich, xanthine-rich food or&#xD;
             beverages and other special diets that affect drug absorption, distribution,&#xD;
             metabolism, and excretion during the period from screening to -1 day;&#xD;
&#xD;
         17. (Inquiry) Those who cannot eat or have difficulty swallowing, have special dietary&#xD;
             requirements and/or cannot follow a unified diet;&#xD;
&#xD;
         18. (Inquiry) Those who have a history of asthma or seizures;&#xD;
&#xD;
         19. (Inquiry) Those who have used any drugs within 1 month before the trial;&#xD;
&#xD;
         20. (Inquiries) Machine operators who are engaged in high-altitude operations, motor&#xD;
             vehicle driving and other dangerous machinery operators;&#xD;
&#xD;
         21. (Inquiry) Those who cannot tolerate venipuncture and/or have a history of fainting&#xD;
             blood and needles;&#xD;
&#xD;
         22. (Inquiry) People with a history of hereditary galactose intolerance, lactase&#xD;
             deficiency or glucose-galactose malabsorption;&#xD;
&#xD;
         23. (Inquiry) Those who have used any drugs within one year before the trial;&#xD;
&#xD;
         24. Alcohol breath test results greater than 0.0mg/100ml or those who are positive for&#xD;
             drug abuse screening (morphine, methamphetamine, ketamine, amphetamine,&#xD;
             tetrahydrocannabinol acid, cocaine) );&#xD;
&#xD;
         25. Subjects considered by the investigator to have poor compliance or have any factors&#xD;
             that are not suitable for participating in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yingxue Lv</last_name>
    <phone>＋86-22-24929667</phone>
    <email>lvyingxue@hemay.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weiyong Li</last_name>
    <phone>＋86-27-85726685</phone>
    <email>2621239868@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>weiyong Li, Ph.D.</last_name>
      <phone>86-27-85726685</phone>
      <email>2621239868@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

